Amylyx Pharmaceuticals Inc

AM LX is in a Stage 2 advancing corrective reset with persistent higher highs and lows, supported by a Lockout Rally pattern that confirms strong institutional demand. Medium-term bias is bullish, permitting long-side participation, and short-term execution is favorable right now due to the Lockout Rally override despite overbought readings. Execution should target shallow pullbacks into the rising 9/21 EMA zone for continuation participation, while acknowledging the long-term downtrend remains a structural headwind.

• ↑Targets 160,000 US PBH patients addressing major unmet medical need
• ↑Phase III Lucidity trial completes in Q3 2026, paving FDA NDA submission
• ↓Q1 2026 EPS loss $0.37 misses consensus $0.33 target